Search results for "modification"

showing 10 items of 853 documents

A Promising Family of Fluorescent Water-Soluble aza-BODIPY Dyes for in Vivo Molecular Imaging.

2019

A new family of water-soluble and bioconjugatable aza-BODIPY fluorophores was designed and synthesized using a boron- functionalization strategy. These dissymmetric bis-ammonium aza-BODIPY dyes present optimal properties for a fluorescent probe; i.e., they are highly water-soluble, very stable in physiological medium; they do not aggregate in PBS, possess high quantum yield; and finally, they can be easily bioconjugated to antibodies. Preliminary in vitro and in vivo studies were performed for one of these fluorophores to image PD-L1 (Programmed Death-Ligand 1), highlighting the high potential of these new probes for future in vivo optical imaging studies.

Boron CompoundsBiomedical EngineeringPharmaceutical ScienceQuantum yieldBioengineering02 engineering and technology01 natural sciencesMiceIn vivoCell Line TumorAza-bodipyAnimalsHumansFluorescent DyesPharmacologyMice Inbred BALB C010405 organic chemistryChemistryOrganic ChemistryWater021001 nanoscience & nanotechnologyCombinatorial chemistryFluorescenceIn vitro0104 chemical sciences3. Good healthMolecular ImagingWater solubleSolubilitySurface modificationHeterograftsMolecular imaging0210 nano-technologyBiotechnologyBioconjugate chemistry
researchProduct

Electronic and Functional Scope of Boronic Acid Derived Salicylidenehydrazone (BASHY) Complexes as Fluorescent Dyes

2017

[EN] A series of boronic acid derived salicylidenehydrazone (BASHY) complexes was prepared and photophysically characterized. The dye platform can be modified by (a) electronic tuning along the cyanine-type axis via modification of the donor-acceptor pair and (b) functional tuning via the boronic acid residue. On the one hand, approach (a) allows the control of photophysical parameters such as Stokes shift, emission color, and two-photon absorption (2PA) cross section. The resulting dyes show emission light-up behavior in nonpolar media and are characterized by high fluorescence quantum yields (ca. 0.5-0.7) and brightness (ca. 35000-40000 M-1 cm(-1)). Moreover, the 2PA cross sections reach …

BrightnessDesignFluorophores010402 general chemistryPhotochemistry01 natural sciencessymbols.namesakechemistry.chemical_compoundResidue (chemistry)ChromophoreMolecular logicStokes shiftMoietyPROYECTOS DE INGENIERIABodipy dyes2-Photon absorptionEnhancement010405 organic chemistryChemistryOrganic ChemistryChromophoreFluorescence0104 chemical sciences3. Good healthsymbolsSurface modificationProbesHighly fluorescentDerivativesBoronic acidThe Journal of Organic Chemistry
researchProduct

Organotin(IV) complexes with epigenetic modulator ligands: New promising candidates in cancer therapy

2022

Organotin(IV) compounds have found their place among a class of non-platinum chemotherapeutic metallo-pharmaceuticals exhibiting good antitumor activity. The cytotoxicity induced by the different kinds of organotins has been related to several mechanism. In this review we report our last decade research activity concerning the synthesis and chemical characterization of new organotin(IV) derivatives containing epigenetic modulator ligand by using, FT-IR, Mössbauer spectroscopy, 119Sn{1H} cross polarization magic angle spinning, electrospray ionization mass spectroscopy, UV–Vis, 1H, 13C{1H} and 119Sn{1H} NMR spectroscopy and density functional theory calculations. The first aim of the biologi…

Caffeic acidInorganic ChemistryEpigenetic modificationValproic acidMaterials ChemistryApoptosisOrganotin(IV)Butyric acidPhysical and Theoretical ChemistryInorganica Chimica Acta
researchProduct

Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method.

2012

Abstract Background In colorectal carcinoma, extensive gene promoter hypermethylation is called the CpG island methylator phenotype (CIMP). Explaining why studies on CIMP and survival yield conflicting results is essential. Most experiments to measure DNA methylation rely on the sodium bisulfite conversion of unmethylated cytosines into uracils. No study has evaluated the performance of bisulfite conversion and methylation levels from matched cryo-preserved and Formalin-Fixed Paraffin Embedded (FFPE) samples using pyrosequencing. Methods Couples of matched cryo-preserved and FFPE samples from 40 colon adenocarcinomas were analyzed. Rates of bisulfite conversion and levels of methylation of …

Cancer ResearchBisulfite sequencing[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaBiologyMLH1lcsh:RC254-282[ SDV.CAN ] Life Sciences [q-bio]/Cancerchemistry.chemical_compound[SDV.CAN] Life Sciences [q-bio]/CancerPredictive Value of TestsBiomarkers TumorGeneticsHumansSulfitesDNA Modification MethylasesAdaptor Proteins Signal TransducingCryopreservationParaffin EmbeddingTumor Suppressor ProteinsNuclear ProteinsReproducibility of ResultsDNA NeoplasmMethylationDNA MethylationPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensMolecular biologydigestive system diseasesNeoplasm ProteinsBisulfiteDNA Repair EnzymesLong Interspersed Nucleotide ElementsPhenotypeOncologyCpG sitechemistrySodium bisulfiteColonic NeoplasmsDNA methylationFeasibility StudiesPyrosequencingCpG IslandsMutL Protein Homolog 1Research Article
researchProduct

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53

2009

Malignant melanomas are highly resistant to chemotherapy. First-line chemotherapeutics used in melanoma therapy are the methylating agents dacarbazine (DTIC) and temozolomide (TMZ) and the chloroethylating agents BCNU and fotemustine. Here, we determined the mode of cell death in 11 melanoma cell lines upon exposure to TMZ and fotemustine. We show for the first time that TMZ induces apoptosis in melanoma cells, using therapeutic doses. For both TMZ and fotemustine apoptosis is the dominant mode of cell death. The contribution of necrosis to total cell death varied between 10 and 40%. The O(6)-methylguanine-DNA methyltransferase (MGMT) activity in the cell lines was between 0 and 1100 fmol m…

Cancer ResearchProgrammed cell deathDNA repairDacarbazineBlotting WesternApoptosistemozolomideBiologyCollagen Type XIDNA Mismatch RepairNecrosisGliomaAntineoplastic Combined Chemotherapy ProtocolsTumor Cells CulturedmedicineHumansDNA Breaks Double-StrandedEverolimusPhosphorylationDNA Modification MethylasesMelanomaneoplasmsSirolimusTemozolomideTumor Suppressor ProteinsMelanomafotemustinemelanoma therapymedicine.diseaseDacarbazineEnzyme Activationmismatch repairDNA Repair EnzymesOncologyApoptosisCaspasesCancer researchFotemustineTumor Suppressor Protein p53Translational TherapeuticsMGMTmedicine.drugBritish Journal of Cancer
researchProduct

Pharmacological targeting of the novel β-catenin chromatin-associated kinase p38α in colorectal cancer stem cell tumorspheres and organoids

2021

AbstractThe prognosis of locally advanced colorectal cancer (CRC) is currently unsatisfactory. This is mainly due to drug resistance, recurrence, and subsequent metastatic dissemination, which are sustained by the cancer stem cell (CSC) population. The main driver of the CSC gene expression program is Wnt signaling, and previous reports indicate that Wnt3a can activate p38 MAPK. Besides, p38 was shown to feed into the canonical Wnt/β-catenin pathway. Here we show that patient-derived locally advanced CRC stem cells (CRC-SCs) are characterized by increased expression of p38α and are “addicted” to its kinase activity. Of note, we found that stage III CRC patients with high p38α levels display…

Cancer ResearchSettore MED/06 - Oncologia Medicapost-translationalImmunologyPopulationSynthetic lethalityArticleCellular and Molecular NeuroscienceCancer stem cellchromatin; colorectal neoplasms; humans; mitogen-activated protein kinase 14; neoplastic stem cells; organoids; prognosis; protein processing post-translational; beta cateninMedicineKinase activitycolon cancer p38 cancer stem cellslcsh:QH573-671educationhumansmitogen-activated protein kinase 14organoidsTrametinibSettore MED/04 - Patologia Generaleeducation.field_of_studybusiness.industrylcsh:CytologyCancer stem cellsneoplastic stem cellsWnt signaling pathwayprotein processingCell Biologycolorectal neoplasmsColorectal cancerdigestive system diseasesSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaCateninCancer researchbeta cateninchromatinprognosisStem cellSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratoriobusinessProtein Processing Post-TranslationalPost-translational modifications
researchProduct

Refining sorafenib therapy: lessons from clinical practice

2015

ABSTRACT  Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symp…

Cancer ResearchSettore SECS-P/06 - Economia ApplicataAntineoplastic AgentAge FactorChild–Pugh Bpostprogression treatmentresponse assessmentdose modificationClinical Trials as TopicLiver Neoplasmsadverse event managementAge FactorsChild-Pugh Bpostprogression treatmenthepatocellular carcinomaGeneral MedicinePrognosisadverse event management; child–Pugh B; dose modification; elderly hepatocellular carcinoma; mRECIST; postprogression treatment; eal-world data; response assessment; sorafenibelderly hepatocellular carcinomaCombined Modality Therapychild–Pugh BClinical PracticeTreatment OutcomeOncologyLiver Neoplasmeal-world dataHepatocellular carcinomaadverse event managementRetreatmentDisease Progressiondose modificationHumanmedicine.drugPhenylurea CompoundNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularDisease ResponsePrognosielderly hepatocellular carcinomaProtein Kinase InhibitorAntineoplastic AgentsmRECISTelderlymRECISTAdverse event management Child–Pugh B dose modification elderly hepatocellular carcinoma mRECIST postprogression treatment real-world data response assessment sorafenibmedicineChild–Pugh BHumansCombined Modality TherapyIntensive care medicineAdverse effectProtein Kinase InhibitorsDose Modificationreal-world databusiness.industryPhenylurea Compoundsmedicine.diseaseDiscontinuationSurgeryreal-world dataresponse assessmentsorafenibbusinessFuture Oncology
researchProduct

2015

Elongator is a conserved protein complex comprising six different polypeptides that has been ascribed a wide range of functions, but which is now known to be required for modification of uridine residues in the wobble position of a subset of tRNAs in yeast, plants, worms and mammals. In previous work, we showed that Elongator's largest subunit (Elp1; also known as Iki3) was phosphorylated and implicated the yeast casein kinase I Hrr25 in Elongator function. Here we report identification of nine in vivo phosphorylation sites within Elp1 and show that four of these, clustered close to the Elp1 C-terminus and adjacent to a region that binds tRNA, are important for Elongator's tRNA modification…

Cancer ResearchTRNA modificationProtein subunitSaccharomyces cerevisiaeWobble base pairBiologybiology.organism_classificationBiochemistryCasein Kinase ITransfer RNAGeneticsPhosphorylationProtein kinase AMolecular BiologyGenetics (clinical)Ecology Evolution Behavior and SystematicsPLOS Genetics
researchProduct

Gene Amplification-Associated Overexpression of the Selenoprotein tRNA Enzyme TRIT1 Confers Sensitivity to Arsenic Trioxide in Small-Cell Lung Cancer

2021

Simple Summary Small-cell lung cancer accounts for approximately 13% of all new lung cancer diagnoses, but in contrast to non-small-cell lung cancer, the implementation of targeted treatments in small-cell lung cancer has been limited, with little improvement in the clinical outcome in the last several decades. Exploring new pathways for targeted therapy, we have observed that extra-copies of the tRNA modifier TRIT1, involved in the translation of selenoproteins, confers sensitivity to arsenic trioxide in small-cell lung cancer. This finding could open a new therapeutic niche for a tumor type with such a dismal clinical course. The alteration of RNA modification patterns is emerging as a co…

Cancer Researchgene amplificationCellTRIT1lcsh:RC254-282Articlechemistry.chemical_compoundRNA modificationsGene duplicationmedicinesmall-cell lung cancerArsenic trioxideGenechemistry.chemical_classificationSelenocysteineChemistryRNAlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenstransfer RNACell biologymedicine.anatomical_structureOncologyTransfer RNAselenoproteinsCàncer de pulmóRNASelenoproteinLung cancer
researchProduct

MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and …

2010

The DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) is a key player in tumor cell resistance. Promoter methylation, MGMT activity and immunohistochemistry are used for determining the MGMT status. However, it is unclear whether MGMT promoter methylation correlates with MGMT activity and whether MGMT promoter methylation of the pretreatment tumor predicts the MGMT status of recurrences. To address these questions, we determined MGMT activity promoter methylation and immunoreactivity in pretreatment and recurrent glioblastomas (GB, WHO Grade IV), and in astrocytomas (WHO Grade III). We show that GB that were promoter methylated display a range of 0-62 fmol/mg MGMT and tumor…

Cancer Researchmedicine.medical_specialtyPathologyMethyltransferaseDNA repairAstrocytomaBiologyRecurrenceCell Line TumormedicineHumansPromoter Regions GeneticDNA Modification MethylasesneoplasmsBrain NeoplasmsTumor Suppressor ProteinsAstrocytomaCancerAnatomical pathologyBiological activityMethylationDNA Methylationmedicine.diseaseImmunohistochemistrydigestive system diseasesDNA Repair EnzymesOncologyCancer researchImmunohistochemistryGlioblastomaInternational Journal of Cancer
researchProduct